PMID- 19170716
OWN - NLM
STAT- MEDLINE
DCOM- 20091230
LR  - 20220223
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 71
IP  - 5
DP  - 2009 Nov
TI  - Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory 
      protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) 
      and associated with adiposity, but unaffected by pioglitazone treatment.
PG  - 652-8
LID - 10.1111/j.1365-2265.2009.03523.x [doi]
AB  - OBJECTIVE: Hirsutism is most often caused by polycystic ovary syndrome (PCOS). 
      PCOS patients are characterized by insulin resistance, abdominal obesity and 
      low-grade inflammation. Insulin sensitizing treatment reduces the inflammatory 
      state, but the effect on serum levels of migration inhibitor factor (MIF), 
      monocyte chemoattractant protein (MCP)-1 and macrophage inflammatory protein 
      (MIP)-1alpha have not been evaluated before in PCOS. RESEARCH DESIGN AND METHODS: 
      Plasma chemokine levels (MCP-1, MIP-1alpha and MIF) were measured in two study 
      designs. (i) 51 hirsute patients and 63 matched controls and (ii) 30 PCOS 
      patients before and after randomized treatment with 30 mg pioglitazone/placebo 
      for 16 weeks. Clinical evaluations and whole body DXA-scans were performed in all 
      participants. RESULTS: Hirsute patients (n = 51) had significantly increased 
      MCP-1 [121 (15-950) vs. 81 (18-365) pg/ml; P < 0.05] and MIP-1alpha[179 (8-4202) 
      vs. 103 (4-1598) pg/ml; P < 0.05] than controls of matched body composition 
      [geometric mean (-2SD to +2SD)]. In PCOS (n = 30), MCP-1, MIP-1alpha and MIF 
      correlated positively with central fat mass. A BMI independent positive 
      association was found between MIF and free testosterone (r = 0.49, P = 0.01) in 
      PCOS. Pioglitazone treatment significantly improved insulin sensitivity without 
      affecting testosterone, body composition, MCP-1, MIP-1alpha and MIF levels. 
      CONCLUSIONS: Chemokine levels were significantly increased and showed close 
      associations with measures of adiposity in PCOS patients, but were unchanged 
      during insulin sensitizing treatment with pioglitazone. Our data suggests a fat 
      mass independent association between testosterone and MIF levels in PCOS and the 
      effect of anti-androgen treatment on chemokine levels needs to be examined.
FAU - Glintborg, Dorte
AU  - Glintborg D
AD  - Department of Endocrinology and Metabolism, Odense University Hospital, 
      Klovervaenget 6, Odense C, Denmark. dorte.glintborg@dadlnet.dk
FAU - Andersen, Marianne
AU  - Andersen M
FAU - Richelsen, Bjorn
AU  - Richelsen B
FAU - Bruun, Jens M
AU  - Bruun JM
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090119
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Macrophage Migration-Inhibitory Factors)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Triglycerides)
RN  - 3XMK78S47O (Testosterone)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.2.1 (MIF protein, human)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adiposity/*physiology
MH  - Chemokine CCL2/*blood
MH  - Chemokine CCL3/*blood
MH  - Cholesterol/blood
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Intramolecular Oxidoreductases/blood
MH  - Lipoproteins, HDL/blood
MH  - Macrophage Migration-Inhibitory Factors/blood
MH  - Pioglitazone
MH  - Polycystic Ovary Syndrome/*blood/*drug therapy
MH  - Radioimmunoassay
MH  - Testosterone/blood
MH  - Thiazolidinediones/*therapeutic use
MH  - Triglycerides/blood
EDAT- 2009/01/28 09:00
MHDA- 2009/12/31 06:00
CRDT- 2009/01/28 09:00
PHST- 2009/01/28 09:00 [entrez]
PHST- 2009/01/28 09:00 [pubmed]
PHST- 2009/12/31 06:00 [medline]
AID - CEN3523 [pii]
AID - 10.1111/j.1365-2265.2009.03523.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2009 Nov;71(5):652-8. doi: 
      10.1111/j.1365-2265.2009.03523.x. Epub 2009 Jan 19.